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Summary We describe a case of a 60-year-old male with dilated phase of hyper-
trophic cardiomyopathy caused by Fabry disease. He was diagnosed to have a cardiac
variant of Fabry disease by an enzyme assay and a right ventricular endomyocardial
biopsy which revealed speciﬁc features of this disease and cardiac involvement wasAtrial ﬂutter;
Ventricular tachycardia;
Cardiac
resynchronization
the sole manifestation. He has developed dilated cardiomyopathy with sustained
atrial ﬂutter and frequent non-sustained ventricular tachycardia requiring isthmus
ablation and cardiac resynchronization therapy with deﬁbrillator.
© 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
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[therapy with
deﬁbrillator
reserved.
ntroduction
abry disease is an X-linked recessive glycosph-
ngolipid storage disorder caused by a deﬁciency
f the lysosomal enzyme -galactosidase A [1].
eft ventricular (LV) hypertrophy is a most com-
on cardiac manifestation in Fabry disease [2,3].
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914-5087/$ — see front matter © 2008 Japanese College of Cardiolo
oi:10.1016/j.jjcc.2008.10.004nd it is recognized that Fabry disease patients are
nown to have systolic and diastolic dysfunction,
nd supraventricular and ventricular arrhythmia
4—6]. To date, the optimal therapies for Fabry dis-
ase with congestive heart failure and arrhythmia
ave not been well described.ase report
60-year-old male patient presented with dysp-
ea and palpitation on mild effort in December
gy. Published by Elsevier Ireland Ltd. All rights reserved.
140 K. Fukuzawa et al.
Figure 1 (A) Twelve-lead ECG recorded in 1995, this shows signs of left ventricular hypertrophy and ST segment
depression with negative T wave (I, aVL, V4-6). (B) Twelve-lead ECG recorded in December 2007 shows typical atrial
ﬂutter and 2:1 to 4:1 atrio-ventricular conduction with left bundle branch block (QRS = 160ms). (C) Sinus rhythm was
maintained after the ablation for atrial ﬂutter (QRS = 160ms). (D) ECG of bi-ventricular pacing shows the narrowing of
QRS duration (130ms).
Table 1 Time course of electrocardiography and echocardiography ﬁndings.
Date of examination May, 1995′ January 4, 2008′ January 30, 2008′ February 8, 2008′
Rhythm Sinus AFL Sinus Paced
Heart rate (bpm) 70 125 71 75
QRS duration (ms) 100 160 160 130
LVDd (mm) 48 57 59 55
LVDs (mm) 32 54 55 48
%FS (%) 33 4.7 7 12
LVEF (%) / 17 24 36
LAD (mm) 38 45 39 39
IVST (mm) 17 17 18 16
PWT (mm) 13 16 16 16
E (cm/s) 37 115 80 42
A (cm/s) 64 / 39 87
E/A 0.6 / 2.1 0.5
Deceleration time (ms) 260 108 126 148
AFL, atrial ﬂutter; FS, fractional shortening; IVST, interventricular septal wall thickness; LAD, left atrial dimension; LVDd, left
ventricular end-diastolic dimension; LVDs, left ventricular end-systolic dimension; LVEF, left ventricular ejection fraction; PWT,
posterior wall thickness.
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Figure 2 (A) Endomyocardial biopsy specimen obtained
from the interventricular septum reveals extensive vac-
uolization of cardiac myocytes, cellular expansion, and
mild ﬁbrosis (hematoxylin and eosin, 200×). (B) Trans-
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007. The blood pressure was 116/98mm Hg. Chest
-ray revealed enlargement of the heart (cardio-
horacic ratio = 62%). A 12-lead electrocardiogram
ECG) showed atrial ﬂutter (mean ventricular rate,
15 bpm, Fig. 1B). Oral drug therapy was initiated
or rate control and anti-coagulation in an outpa-
ient clinic.
Twelve years before presentation (May 1995),
e had received a diagnosis of hypertrophic non-
bstructive cardiomyopathy. ECG showed signs of
V hypertrophy with normal QRS duration (Fig. 1A).
chocardiography showed eccentric LV hypertro-
hy with normal LV systolic function (Table 1). He
ad been treated with atenolol and imidapril for
years. Subsequently, he had discontinued medi-
al treatment because he had no symptoms. There
as no family history of hypertrophic cardiomyopa-
hy or Fabry disease or sudden cardiac death (<50
ears old).
At the beginning of January 2008, however, he
elt severe dyspnea at rest, and was admitted to
ur hospital. Heart rate was 117 bpm and chest X-
ay showed severe congestion of bilateral lung and
leural effusion. Echocardiography showed diffuse
ardiac hypertrophy with LV ejection fraction (LVEF)
f 17% (Table 1), and plasma brain natriuretic pep-
ide (BNP) level was 1239 pg/ml.
Coronary angiography revealed normal coronary
rtery, while left ventriculography revealed severe
V dilatation and systolic dysfunction (LV end-
iastolic volume index = 147ml/m2, LV end-systolic
olume index = 123ml/m2, LVEF = 16%). Right ven-
ricular endomyocardial biopsy was performed.
his revealed central vacuolar degeneration of
yocytes with concentric lamellar structure ‘zebra
odies,’ which are speciﬁc features of Fabry disease
Fig. 2). Leukocyte -galactosidase A activity was
easured and was below normal range (7.4 Agal U,
ut off <17.0 in male). Cardiac magnetic resonance
maging showed hypertrophy of both ventricles.
ate-enhanced signals after gadolinium infusion
ere observed (Fig. 3). The serum creatinine level
as 0.9mg/dl and total of urine peptide levels
as <10mg/(dl day). Since he did not present non-
ardiac signs of Fabry disease such as cutaneous,
enal, or gastrointestinal involvement, he was diag-
osed with a cardiac variant of Fabry disease.
Atrial ﬂutter was conﬁrmed as typical atrial ﬂut-
er by electroanatomical mapping and entrainment
apping. Subsequently, atrial ﬂutter was termi-
ated by linear ablation between inferior vena cava
nd tricuspid annulus, and bi-directional isthmus
lock was successfully veriﬁed.
Twelve-lead ECG revealed sinus rhythm and
ersistent left bundle branch block (QRS dura-
ion = 160ms, Fig. 1C). ECG monitor recording
a
l
(
tission electron microscopy shows the central vacuolar
egeneration of myocytes with concentric lamellar struc-
ure ‘‘zebra bodies’’. The scale bar represents 1m.
evealed frequent episodes of non-sustained ven-
ricular tachycardia (heart rate was 150 bpm and
aximum duration was 13 s).
Although LVEF improved to 24%, transmitral
oppler ﬂow revealed restrictive pattern indicating
evere diastolic dysfunction (Table 1). Analyzing the
V dyssynchrony using tissue Doppler imaging (TDI),
he difference in the time to peak systolic velocity
f 4 LV basal segments [7] (septal, lateral, inferior,
nterior) was 172ms.
Cardiac resynchronization therapy with deﬁbril-
ator (CRTD) was implanted with standard methods
Fig. 1D). After CRTD implantation, LVEF improved
o 36% by decreasing the mechanical dyssynchrony
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Figure 3 (A) Cardiac magnetic resonance imaging shows
hypertrophy of both ventricles. (B) Late-enhanced signals
after gadolinium infusion is observed at the endocardial
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Rlesion (white arrow 1) and papillary muscle (white arrow
2) and mid-layer of interventricular septal wall (white
arrow 3).
(TDI = 96ms). Of interest, the transmitral Doppler
ﬂow pattern was also improved to impaired relax-
ation (Table 1).
Plasma BNP level decreased to 532 pg/ml after
CRTD implantation. Subsequently, oral carvedilol
therapy, which had been intolerable before CRTD
implantation due to hypotension and general
fatigue, was successfully initiated. After the ini-
tiation of carvedilol, plasma BNP level further
decreased to 325 pg/ml at the time of discharge.
6min walk distance increased from 372m to 506m.
The patient’s NYHA functional status improved from
class IV to class I, and he was able to perform activ-
ities involving moderate effort without any cardiac
symptoms.
He has been planned to be treated with enzyme
replacement therapy since several studies have
reported safety and efﬁcacy of this approach [8,9].K. Fukuzawa et al.
iscussion
everal studies have identiﬁed Fabry disease as a
elatively frequent cause of unexplained LV hyper-
rophy [10—12]. Fabry disease is associated with
ubstantial risk for atrial ﬁbrillation in middle-aged
nd elderly patients [5]. As reports of atrial ﬂut-
er in Fabry disease are very rare, frequency and
ptimal treatment of atrial ﬂutter remain unclear.
urthermore, it is recognized that Fabry disease
atients are known to have ventricular tachycar-
ia and occasionally suffer sudden cardiac death
4—6,13]. Since sudden cardiac death can be the
rst manifestation of Fabry disease, careful risk
tratiﬁcation is required.
To date, descriptions of CRT implantation for car-
iac Fabry have been limited [4,5]. In patients with
ardiac Fabry disease, LV end-diastolic dimension is
ncreased and %fractional shortening is decreased
uring follow up [4]. In addition, an increase in QRS
uration is seen [4], although prevalence of car-
iac Fabry disease with left bundle branch block
s not particularly common [5]. Of note, CRT can
lso improve diastolic function [14,15] and diastolic
unction is deteriorated even in the early phase of
abry disease [16,17]. Consequently, cardiac Fabry
isease with both systolic and diastolic dysfunction
an be a candidate for CRT.
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